Chugai Pharmaceutical (OTCMKTS:CHGCY) Raised to Strong-Buy at UBS Group

Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by research analysts at UBS Group to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

Chugai Pharmaceutical Stock Performance

CHGCY traded up $0.53 during mid-day trading on Tuesday, reaching $28.05. 5,033 shares of the stock were exchanged, compared to its average volume of 116,916. The company has a 50 day moving average price of $26.72 and a two-hundred day moving average price of $24.39. The stock has a market capitalization of $92.31 billion, a PE ratio of 35.06 and a beta of 0.63. Chugai Pharmaceutical has a 1 year low of $19.50 and a 1 year high of $31.26.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%. Sell-side analysts expect that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.